Aulos Bioscience, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2020-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://aulosbio.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorMetastatic CancerCutaneous MelanomaNon-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Aulos Bioscience, Inc.
- Target Recruit Count
- 159
- Registration Number
- NCT05267626
- Locations
- 🇺🇸
University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇦🇺Southern Oncology Clinical Research Unit, Bedford Park, South Australia, Australia
🇺🇸START Midwest, Grand Rapids, Michigan, United States
News
No news found